Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Uncaria tomentosa for Reducing Side Effects Caused by Chemotherapy in CRC Patients: Clinical Trial.

Farias IL, Araújo MC, Farias JG, Rossato LV, Elsenbach LI, Dalmora SL, Flores NM, Durigon M, Cruz IB, Morsch VM, Schetinger MR.

Evid Based Complement Alternat Med. 2012;2012:892182. doi: 10.1155/2012/892182.

2.

Uncaria tomentosa-Adjuvant Treatment for Breast Cancer: Clinical Trial.

Santos Araújo Mdo C, Farias IL, Gutierres J, Dalmora SL, Flores N, Farias J, de Cruz I, Chiesa J, Morsch VM, Chitolina Schetinger MR.

Evid Based Complement Alternat Med. 2012;2012:676984. doi: 10.1155/2012/676984.

3.

Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.

Kemeny N, Garay CA, Gurtler J, Hochster H, Kennedy P, Benson A, Brandt DS, Polikoff J, Wertheim M, Shumaker G, Hallman D, Burger B, Gupta S.

J Clin Oncol. 2004 Dec 1;22(23):4753-61. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248.

PMID:
15570076
4.

[Adjuvant chemotherapy with FOLFOX4 regimen after curative resection of liver metastases from colorectal cancer].

Ohnishi T, Kanoh T, Tono T, Danno K, Watanabe A, Nakamura H, Tsukao Y, Inatome J, Kim T, Kagara N, Taniguchi H, Kimura Y, Nakano Y, Monden T, Imaoka S.

Gan To Kagaku Ryoho. 2010 Nov;37(12):2554-6. Japanese.

PMID:
21224637
5.

A systematic overview of chemotherapy effects in colorectal cancer.

Ragnhammar P, Hafström L, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care..

Acta Oncol. 2001;40(2-3):282-308. Review.

PMID:
11441937
6.

Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer.

Fuse N, Doi T, Ohtsu A, Takeuchi S, Kojima T, Taku K, Tahara M, Muto M, Asaka M, Yoshida S.

Jpn J Clin Oncol. 2007 Jun;37(6):434-9.

7.

Antitumoral and antioxidant effects of a hydroalcoholic extract of cat's claw (Uncaria tomentosa) (Willd. Ex Roem. & Schult) in an in vivo carcinosarcoma model.

Dreifuss AA, Bastos-Pereira AL, Avila TV, Soley Bda S, Rivero AJ, Aguilar JL, Acco A.

J Ethnopharmacol. 2010 Jul 6;130(1):127-33. doi: 10.1016/j.jep.2010.04.029.

PMID:
20435132
8.

Effect of Uncaria tomentosa Extract on Apoptosis Triggered by Oxaliplatin Exposure on HT29 Cells.

de Oliveira LZ, Farias IL, Rigo ML, Glanzner WG, Gonçalves PB, Cadoná FC, Cruz IB, Farias JG, Duarte MM, Franco L, Bertol G, Colpo E, Brites PC, Rocha JB, Leal DB.

Evid Based Complement Alternat Med. 2014;2014:274786. doi: 10.1155/2014/274786.

9.

A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer.

Ramanathan RK, Bjarnason GA, Bernard SA, Desimone P, Braich T, Evars JP, Hrushesky WJ, Jolivet J.

Clin Colorectal Cancer. 2008 Mar;7(2):134-9.

PMID:
18501073
12.
13.

[PSK decreased FOLFOX4-induced peripheral neuropathy and bone marrow suppression in patients with metastatic colorectal cancer].

Shibata M, Shimura T, Nishina Y, Gonda K, Matsuo S, Abe H, Yajima Y, Nakamura I, Ohki S, Takenoshita S.

Gan To Kagaku Ryoho. 2011 May;38(5):797-801. Japanese.

PMID:
21566440
14.

Role of oxaliplatin in the treatment of colorectal cancer.

Comella P, Casaretti R, Sandomenico C, Avallone A, Franco L.

Ther Clin Risk Manag. 2009 Feb;5(1):229-38.

15.

The value of oxaliplatin in combination with continuous infusion +/- bolus 5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the Study of Digestive Tract) cancer phase II trial.

Mosconi S, Cascinu S, Zaniboni A, Catalano V, Giordani P, Beretta GD, Martignoni G, Pancera G, Baldelli AM, Poletti P, Curti C, Labianca R.

Tumori. 2000 Nov-Dec;86(6):465-9.

PMID:
11218187
16.

Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.

Aballéa S, Chancellor JV, Raikou M, Drummond MF, Weinstein MC, Jourdan S, Bridgewater J.

Cancer. 2007 Mar 15;109(6):1082-9.

17.

Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.

Milla P, Airoldi M, Weber G, Drescher A, Jaehde U, Cattel L.

Anticancer Drugs. 2009 Jun;20(5):396-402. doi: 10.1097/CAD.0b013e32832a2dc1.

PMID:
19287306
18.

[Retrospective analysis of FOLFOX4 neurotoxicity for recovery from advanced colorectal cancer].

Matsuda M, Matsusaka S, Kuboki Y, Itimura T, Ogura M, Suenaga M, Syouji D, Watanabe C, Chin K, Mizunuma N, Hatake K.

Gan To Kagaku Ryoho. 2008 Mar;35(3):461-6. Japanese.

PMID:
18347395
19.

Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.

Chang MH, Lee IK, Si Y, Lee KS, Woo IS, Byun JH.

Cancer Chemother Pharmacol. 2011 Aug;68(2):317-23. doi: 10.1007/s00280-010-1496-5.

PMID:
20972872
20.

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A.

J Clin Oncol. 2009 Jul 1;27(19):3109-16. doi: 10.1200/JCO.2008.20.6771.

PMID:
19451431
Items per page

Supplemental Content

Support Center